CNSX:CLPharmaceuticals
Cresco Labs (CNSX:CL) Is Up 55.2% After Cannabis Rescheduling News Is The Bull Case Changed?
Cresco Labs recently welcomed the U.S. federal government’s move to reschedule cannabis from Schedule I to Schedule III, calling it a historic policy shift for the regulated cannabis industry.
The company highlighted that rescheduling could ease tax burdens, improve access to banking and research, and further legitimize state-regulated cannabis markets, directly supporting its brand-building and expansion efforts.
We’ll now examine how easing federal tax burdens and banking frictions could...